Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.

Ann Thorac Cardiovasc Surg · 2026 · PMC13423280 · PMID 42528212

Europe PMC DOI

hedged sentences

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

a favorable trendP = 0.067so close (0.05 < p ≤ 0.1)

After PSM, OS remained nonsignificant (P = 0.202), whereas DFS showed a favorable trend toward improvement in the nivolumab group, with 1-year DFS rates of 75.0% versus 68.8% and 3-year DFS rates of 68.2% versus 19.3%, respectively (P = 0.067).

also in 1,335 other papers

a nonsignificant trendno p-value reported

The HR for adjuvant nivolumab shifted from above one in the univariable analysis to below one after adjustment for ypT and ypN (HR 0.602 [0.240–1.511], P = 0.280), suggesting a nonsignificant trend toward reduced DFS risk.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.